Nixon Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 20-06-2024
- Paid Up Capital ₹ 0.50 M
as on 20-06-2024
- Company Age 15 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.95 M
as on 20-06-2024
- Revenue -12.56%
(FY 2020)
- Profit -52.68%
(FY 2020)
- Ebitda 5.10%
(FY 2020)
- Net Worth 5.22%
(FY 2020)
- Total Assets 7.59%
(FY 2020)
About Nixon Biotech
The Corporate was formerly known as Nixon Biotech & Foods Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹6.95 M.
Ravi Goel, Raghav Goel, and Padam Goyal serve as directors at the Company.
- CIN/LLPIN
U74120PB2009PTC032838
- Company No.
032838
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 May 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Ludhiana, Punjab, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Nixon Biotech Private Limited offer?
Nixon Biotech Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, HIV Drugs, Diabetic Herbal Medicine, Diabetes Powder.
Who are the key members and board of directors at Nixon Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Padam Goyal  | Managing Director | 14-May-2009 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ravi Goel | Director | 14-May-2009 | Current |
| Raghav Goel | Director | 15-Sep-2017 | Current |
Financial Performance of Nixon Biotech.
Nixon Biotech Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 12.56% decrease. The company also saw a substantial fall in profitability, with a 52.68% decrease in profit. The company's net worth moved up by a moderate rise of 5.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nixon Biotech?
In 2020, Nixon Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 27 Sep 2022 | ₹1.05 M | Open |
Punjab National Bank Creation Date: 23 Feb 2016 | ₹2.40 M | Open |
Punjab National Bank Creation Date: 19 Mar 2010 | ₹3.50 M | Open |
How Many Employees Work at Nixon Biotech?
Unlock and access historical data on people associated with Nixon Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nixon Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nixon Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
